NKTR Overview

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Wall Street analysts forecast NKTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTR is123.43 USD with a low forecast of 102.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nektar Therapeutics revenue for the last quarter amounts to 21.81M USD, decreased -25.25

Nektar Therapeutics. EPS for the last quarter amounts to -1.77 USD, decreased -440.38

Nektar Therapeutics (NKTR) has 63 emplpoyees as of April 22 2026.

Today NKTR has the market capitalization of 2.91B USD.